Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Reports $2.6M in Revenues for Q1

NEW YORK, April 30 - Compugen today reported revenues of $2.6 million and a net loss of $2.3 million for the first quarter ending March 31.

 

Revenues, which included $455,000 from R&D grants, were down from the $2.8 million for the year-ago quarter, The Tel Aviv, Israel-based firm said. Net loss, including a non-cash charge of $94,000 for amortization of deferred compensation, dropped from the year-ago quarter's loss of $3.2 million. The company reported R&D expenses of   $3.2 million for the quarter, compared to $3.4 million for the same quarter in 2002.

 

The company reported $67.3 million in cash, cash equivalents and securities on hand as of March 32, comparable to the year-ago quarter and including a $1.7 million private placement by its ag-bio subsidiary Evogen.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.